Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Lila Poiteau"'
Autor:
Christophe Rodriguez, Guillaume Gricourt, Melissa Ndebi, Vanessa Demontant, Lila Poiteau, Sonia Burrel, David Boutolleau, Paul-Louis Woerther, Vincent Calvez, Sebastian Stroer, Jean-Michel Pawlotsky
Publikováno v:
Emerging Infectious Diseases, Vol 26, Iss 6, Pp 1287-1290 (2020)
We report the discovery of a new orthobunyavirus, Cristoli virus, by means of shotgun metagenomics. The virus was identified in an immunodepressed patient with fatal encephalitis. Full-length genome sequencing revealed high-level expression of a viru
Externí odkaz:
https://doaj.org/article/48717d0d492643d7838b0c736302168a
Autor:
Folly Anyovi, Lila Poiteau, Alexandre Soulier, Reham Soliman, Simplice Karou, Gamal Shiha, Jacques Simpore, Stéphane Chevaliez
Publikováno v:
Medical Journal of Viral Hepatitis. :8-13
Autor:
Vanessa Démontant, Jean-Michel Pawlotsky, Sonia Burrel, Guillaume Gricourt, Christophe Rodriguez, David Boutolleau, Lila Poiteau, Paul-Louis Woerther, Melissa N'Debi, Vincent Calvez, Sébastian Ströer
Publikováno v:
Emerging Infectious Diseases, Vol 26, Iss 6, Pp 1287-1290 (2020)
Emerging Infectious Diseases
Emerging Infectious Diseases
We report the discovery of a new orthobunyavirus, Cristoli virus, by means of shotgun metagenomics. The virus was identified in an immunodepressed patient with fatal encephalitis. Full-length genome sequencing revealed high-level expression of a viru
Autor:
Slim Fourati, Christophe Hézode, Christophe Rodriguez, Isaac Ruiz, Stéphane Chevaliez, Jean-Michel Pawlotsky, Alexandre Soulier, Lila Poiteau
Publikováno v:
Hepatology. 69:513-523
Hepatitis C virus (HCV) genotype 4 is highly heterogeneous. HCV subtype 4r has been suggested to be less responsive to direct-acting antiviral (DAA) drug treatment than other genotype 4 subtypes. Among 537 DAA-treated patients who experienced a virol
Autor:
Cécile Brouard, Véronique Brodard, Fabien Zoulim, Alexandre Soulier, Stéphane Chevaliez, Jean-Michel Pawlotsky, Caroline Semaille, Vincent Leroy, Flora Donati, Corinne Pioche, Lila Poiteau, Mélanie Darty-Mercier, Christophe Rodriguez, Christine Larsen, Françoise Roudot-Thoraval
Publikováno v:
Journal of Viral Hepatitis
Journal of Viral Hepatitis, Wiley-Blackwell, 2019, 26 (2), pp.278-286. ⟨10.1111/jvh.13025⟩
Journal of Viral Hepatitis, Wiley-Blackwell, 2019, 26 (2), pp.278-286. ⟨10.1111/jvh.13025⟩
Nucleoside and nucleotide analogues (NUCs) targeting hepatitis B virus are capable of selecting resistant viruses upon long-term administration as monotherapies. The prevalence of resistance-associated substitutions (RASs) and fitness-associated subs
Autor:
Christophe Hézode, Lila Poiteau, Jean-Baptiste Trabut, Anne Bourdel, Stéphane Chevaliez, A. Bachelard, Mélanie Wlassow, Stéphanie Dominguez, Françoise Roudot-Thoraval, Johann Volant
Publikováno v:
Open Forum Infectious Diseases
Background Injecting drug use is a major driver of hepatitis C virus (HCV) spread worldwide, and the World Health Organization (WHO) has identified people who inject drugs (PWID) as a key population to target for HCV screening and care. Point-of-care
Publikováno v:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 129
Background Accurate molecular methods to detect and quantify hepatitis B virus (HBV) DNA are essential to diagnose chronic infections, guide treatment decisions, assess response to treatment, and determine risk of HBV-related complications. New HBV D
Autor:
Slim Fourati, Rozenn Brillet, Flora Donati, Abdelhakim Ahmed-Belkacem, Vanessa Démontant, Alexandre Soulier, Guillaume Gricourt, Lila Poiteau, Sabah Hamadat, Christophe Rodriguez, Nazim Ahnou, Stéphane Chevaliez, Jean-Michel Pawlotsky
Publikováno v:
Alimentary Pharmacology and Therapeuthics
Alimentary Pharmacology and Therapeuthics, 2020, 52 (10), pp.1583-1591. ⟨10.1111/apt.16054⟩
Alimentary Pharmacology and Therapeuthics, 2020, 52 (10), pp.1583-1591. ⟨10.1111/apt.16054⟩
International audience; Background: In hepatitis C virus (HCV) infection, treatment failure is generally associated with the selection of resistance-associated substitutions (RAS) conferring reduced susceptibility to direct-acting antiviral (DAA) dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d4326335dda8c5d52c9ce4da2f06e3f
https://hal-pasteur.archives-ouvertes.fr/pasteur-03139183
https://hal-pasteur.archives-ouvertes.fr/pasteur-03139183
Autor:
Christophe Hézode, Slim Fourati, Mélanie Wlassow, Alexandre Soulier, Christophe Rodriguez, Mélanie Mercier-Darty, Stéphane Chevaliez, Jean-Michel Pawlotsky, Lila Poiteau
Publikováno v:
Antiviral Therapy. 24:417-423
Background International liver society guidelines recommended to perform HCV resistance testing at baseline of first-line therapy with certain combination regimens or prior to retreatment in patients previously exposed to a direct-acting antiviral (D
Autor:
Slim Fourati, Christophe Rodriguez, Alexandre Soulier, Lila Poiteau, Demontant Vanessa, Melissa N Debi, Stéphane Chevaliez, Hezode Christophe, Jean-Michel Pawlotsky
Publikováno v:
Journal of Hepatology. 73:S360-S361